About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, November 19th, 2012

The QualityStocks
Daily Stock List

graphic
graphic

Dacha Strategic Metals, Inc. (DSM.V)

ItsAllBull.net reported previously on Dacha Strategic Metals, Inc. (DSM.V), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Dacha Strategic Metals, Inc. is an investment company that lists on the TSX Venture Exchange. The Company focuses on the acquisition, storage and trading of strategic metals with a primary focus on Rare Earth Elements. The Company has their headquarters in Toronto, Ontario. They also have a People's Republic of China office in Beijing. Dacha also lists on the OTCQX International exchange under the symbol "DCHAF".

The Company’s main goal is to achieve, by way of their wholly owned subsidiaries, long-term capital appreciation through the buying, holding and selling of Strategic Minerals, particularly, Rare Earth Elements. They are working to achieve this goal through investing in difficult to access markets by establishing trading relationships and purchasing stockpiles of Strategic Minerals.

Dacha Strategic Metals is in the unique position of holding a commercial stockpile of Physical Rare Earth Elements. The Rare Earths comprise 15 elements known as the Lanthanides in the Periodic Table.  Two other elements are also tied in with Rare Earths, Scandium and Yttrium. Rare Earth elements never appear on their own and always in deposits that contain all 15 elements in various percentages.

Earlier this month, Dacha Strategic Metals reported the estimated market value of their Rare Earth metals inventory. As of October 31, 2012, the estimated value of their metals inventory was US$43.4 million. This represents a decrease of US$9.0 million, or 17.2 percent, from the estimated value of US$52.4 million at September 30, 2012, as reported in their October 1, 2012 press release.

Assets include metal inventory and cash. At October 31, 2012, in addition to their metal inventory (estimated fair market value of US$43.4 million) the Company had cash of approximately US$2.5 million for a total of US$45.9 million, or US$0.61 per share, based on 75.1 million shares outstanding, or, US$0.59 per share on a fully diluted basis of 92.4 million shares outstanding.

Dacha Strategic Metals, Inc. (DSM.V), closed Monday's trading session at $0.455, up 13.75%, on 637,400 volume. The stock's 52-week low/high is $0.33/$0.59.

iTrackr Systems, Inc. (IRYS)

Penny Sleuth, SmallCap Network, OTCJournal, The Stock Psycho, TopGun, WhisperFromWallStreet, and Otcstockexchange reported earlier on iTrackr Systems, Inc. (IRYS), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Headquartered in Boca Raton, Florida, iTrackr Systems, Inc. is an e-commerce and social media software and services company. They serve an array of industries with a focus on e-commerce markets primarily in North America. The Company was founded in 2006 and their shares trade on the OTC Bulletin Board.

iTrackr Systems built and they now operate iTrackr.com. This is a direct deals platform containing more than a million business profiles. The design of it is to enable consumers and their local merchants the ability and independence to negotiate discounts directly when they want and how they want.

iTrackr.com introduces a way to put the consumer in complete control of lowering their cost of living. With the iTrackr.com platform, business owners can send out deals to all consumer profiles based on identified interest within a 25-mile radius of their operation. The consumer can request a specific and personalized deal directly through any business with an iTrackr.com profile also located within a 25-mile radius of the consumer's home address.

Additionally, through their wholly owned subsidiary, RespondQ, iTrackr Systems provides innovative chat technology through licensing. The Company is also the first in their class to also offer a Full Service and Pay for Performance model to qualifying site owners. RespondQ is the only entity in the market that provides a comprehensive Chat solution with a Pay for Performance model, the RQ FX Solution. At RespondQ, they view Chat as a new channel for companies to interact with their customers. RespondQ proactively approaches a client's visitors to assist them with their product search and purchase when they are actively looking at a client's site.

iTrackr Systems' offers their RQ Support. With RQ Support, members gain direct access to a dedicated team of technical support professionals. The Company's technical support professionals are available to help set up new equipment and software or resolve issues with personal computers (PCs), home networks, scanners, printers, Internet connections, smartphones, digital cameras, digital video recorders, small business networks and more.

In June 2012, iTrackr Systems announced that RespondQ reached an agreement with leading International website broker, Latona's (latonas.com), a major re-seller of website properties, to utilize chat technology on their website. Latona's added RespondQ chat technology to online properties Latonas.com and DigiPawn.com.

iTrackr Systems, Inc. (IRYS), closed Monday's trading session at $0.11, up 4.76%, on 26,300 volume with 5 trades. The average volume for the last 60 days is 21,162 and the stock's 52-week low/high is $0.08/$0.845.

Aeolus Pharmaceuticals, Inc. (AOLS)

Ceocast News reported earlier on Aeolus Pharmaceuticals, Inc. (AOLS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Aeolus Pharmaceuticals, Inc. is developing a new class of catalytic antioxidant compounds that protects healthy tissue from the damaging effects of radiation. The Company's first compound, AEOL 10150, is undergoing development for oncology indications, where it is used in combination with radiation therapy. Aeolus Pharmaceuticals has their corporate headquarters in Mission Viejo, California. Aeolus has more than $150M of government funding supporting their development programs. Founded in 1994, the Company's shares trade on the OTC Markets: OTCQB.

Aeolus Pharmaceuticals' AEOL 10150 is also undergoing development, with funding by the US Government, as a medical countermeasure against chemical and radiological weapons. Its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure.

The Company's strategy is to take advantage of the significant investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with the Biomedical Advanced Research and Development Authority (BARDA) valued, with options, at up to $118 million, to develop the compound efficiently for use in oncology.

AEOL 10150 protects healthy tissue from the damaging effects of radiation and helps increase tumor control when used in combination with radiation and chemotherapy. AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure

In addition, AEOL 10150 is currently at Technical Readiness Level (TRL) 7 as a medical countermeasure (MCM) for GI-ARS and Lung-ARS (Acute Radiation Syndromes). Both of these are caused by exposure to high levels of radiation due to a radiological or nuclear event.

AEOL 10150 has demonstrated safety in animal studies, been well tolerated in two human clinical trials, demonstrated efficacy in two species in ARS studies, and demonstrated statistically significant survival efficacy in an acute radiation‐induced lung injury model. Additionally, AEOL 10150 has demonstrated efficacy in validated animal models for GI‐ARS, chlorine gas exposure, and sulfur mustard gas exposure.

Aeolus Pharmaceuticals, Inc. (AOLS), closed Monday's trading session at $0.27, down 22.86%, on 69,801 volume with 11 trades. The average volume for the last 60 days is 10,854 and the stock's 52-week low/high is $0.21/$0.46.

Cicero, Inc. (CICN)

OTCPicks reported previously on Cicero, Inc. (CICN), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Based in Cary, North Carolina, Cicero, Inc. provides solutions that enable business transformation of enterprise interactions across companies and government organizations. The Company is a worldwide provider of Customer Experience Management (CEM) and integration technologies. The design of the Company's products is to give businesses accurate information concerning performance and to reshape data to drive specific work and service outcomes. Cicero XM® technology allows business and Information Technology (IT) to "find" problems with applications and the use of them. Cicero's shares trade on the OTC Bulletin Board.

Cicero XM® technology delivers solutions by way of an innovative combination of desktop integration, automation, presentation and analytics capabilities. These are built to transform customer interaction into the most powerful marketing and branding asset a business can own. Cicero software solutions feature ease of configuration and change control, eliminating up to 90 percent of the change control costs and time, providing the ability to deliver actionable intelligence via an efficient combination of telephony and interaction data, and delivering immediate benefits with a Return on Investment (ROI) in less than six months.

Cicero XM is a CEM solution for contact centers and the enterprise. It simplifies workflow, automates tasks, as well as automatically shares data between any applications from back office to desktop servicing solutions. Cicero XM is a non-invasive solution; it does not require taking away or hiding users' access to existing applications. It simplifies, extends, and automates processes using those applications while allowing new applications to undergo integration simply and rapidly. Cicero XM also features tools to create a modular, customizable interface, scripting or user guidance, screen pops, new composite applications, and a robust toolbar.

This past September, Cicero and Pipkins, Inc. announced that they would deploy Vantage Point™ with Cicero's desktop analytics technology to customers. The addition of Cicero's desktop analytics technology extends Vantage Point's data collection capabilities at the employee desktop to identify operational issues in contact centers and the back office. It enhances Vantage Point's forecasting, scheduling, and planning functionality for enterprise-wide workforce management allowing companies to automate processes and reduce costs. Pipkins is a leading supplier of workforce management software.

Cicero, Inc. (CICN), closed Monday at $0.065, up 18.18%, on 90,857 volume with 7 trades. The average volume for the last 60 days is 11,526 and the stock's 52-week low/high is $0.035/$0.21.

BlueFire Renewables, Inc. (BFRE)

SmallCapVoice, OTC Picks, M2 Communications, and FeedBlitz reported previously on BlueFire Renewables, Inc. (BFRE), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

BlueFire Renewables, Inc.'s primary business includes development activities culminating in the design, construction, ownership and long-term operation of cellulosic ethanol production biorefineries utilizing the licensed Arkenol Technology in North America. The Company's secondary business is providing support and operational services to Arkenol Technology based biorefineries globally. BlueFire Renewables is based in Irvine, California.

Founded in 2006, the Company is currently in the development-stage of finding suitable locations and deploying project opportunities for converting cellulose fractions of municipal solid waste and other opportunistic feedstock into ethanol fuels. BlueFire Renewables established to deploy a patented Concentrated Acid Hydrolysis Technology Process for the conversion of cellulosic (Green Waste) waste materials to ethanol, and other viable alternatives to petroleum-derived fuels.

The Company's technology has demonstrated production of ethanol and other petroleum displacing fuels from urban trash (post-sorted MSW), rice and wheat straws, wood waste and other agricultural residues. BlueFire is the exclusive North America licensee of the Arkenol Technology.

BlueFire Renewables initial planned biorefineries in North America include a biorefinery that will process approximately 190 tons of green waste material annually to produce approximately 3.9 million gallons of ethanol annually. On November 9, 2007, the Company purchased the facility site that is in Lancaster, California for the BlueFire Ethanol Lancaster project (Lancaster Biorefinery)

The Company's plans also include a biorefinery proposed for development and construction in conjunction with the DOE, previously located in Southern California, and now located in Fulton, Mississippi. This biorefinery will process approximately 700 metric dry tons of woody biomass, mill residue, and other cellulosic waste to produce approximately 19 million gallons of ethanol annually (Fulton Project). In addition, BlueFire is evaluating several other opportunities in North America.

In November 2011, the Company created SucreSource LLC, a wholly owned subsidiary working to partner with synergistic back end companies that need cellulosic sugars as a feedstock for their fermentation or chemical processes. SucreSource will utilize the Arkenol process to provide the front-end technology to collaborate with these companies.

In February 2012, SucreSource received their first payment from the professional services agreement (PSA) with GS Caltex. BlueFire Renewables has completed Phase 1 and Phase 2 of development for the cellulosic sugar production facility located at a GS Caltex facility in South Korea. GS Caltex is a Korean oil and petrochemical company.

BlueFire Renewables, Inc. (BFRE), closed Monday's session at $0.1372, down 2.00%, on 43,197 volume with 4 trades. The average volume for the last 60 days is 1,839 and the stock's 52-week low/high is $0.0821/$0.59.

Chancellor Group, Inc. (CHAG)

SmallCapVoice reported earlier on Chancellor Group, Inc. (CHAG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Chancellor Group, Inc. is an emerging energy and natural resources company whose shares trade on the OTC Bulletin Board. The Company acquires, explores, and develops oil and gas properties. In April 2007, Chancellor began operations with what were 84 actually producing wells in Gray and Carson counties, Texas. On July 22, 2008, the Company entered into an Agreement, effective as of June 1, 2008 with Legacy Reserves Operating, LP for the sale of their oil and gas wells in Carson County, Texas, representing approximately 84 percent of Chancellor's oil and gas production at that time. Chancellor Group has their headquarters in Texas.

In 2010, Chancellor acquired three additional properties in Hutchinson County including approximately 16 wells. In 2011, they continued their operational, restoration programs, and the production capacity from their 67 actively producing wells in Gray and Hutchinson counties. Through a Purchase and Sale Agreement dated October 18, 2011, LCB Resources purchased all of Gryphon's right, title and interest in certain leases, wells, equipment, contracts, data and other designated property, effective December 31, 2011. The assets sold to LCB approximated 82 percent of Chancellor Group's consolidated total assets as of September 30, 2011. Under the terms of the Agreement, LCB paid Gryphon $2,050,000 in cash.  

Chancellor Group has continued to maintain four producing wells and one water disposal well. Gryphon retains an operator's license with the Texas Railroad Commission and continues to operate the Hood leases. The proceeds from the asset sale will be used to provide working capital to Chancellor and for future corporate purposes. This includes, but is not limited to, possible acquisitions and other corporate programs and purposes that the Company has yet to identify.

As of March 31, 2012, Chancellor Group owned the aforementioned approximately four actively producing oil wells and one water disposal well located in Gray County in Texas; and produced a total of 390 barrels of oil. During the three months ended September 30, 2012, they produced and sold 72 barrels of oil, generating $6,308 of revenues net of royalties, with a one-month lag in receipt of revenues for the prior month's sales. This is in comparison to 2,251 barrels of oil and 2,165 mcf of gas, generating $199,794 in gross revenues net of royalties paid during the same period in 2011.

In addition, Chancellor Group has opened a new division to explore business opportunities into commercial internet sites including social network sites or related sites involved in internet e-commerce. This would be in addition to the Company's committed interest in looking for new oil and/or gas projects. Activity related to this new division for the Company has not been material through September 30, 2012.

Chancellor Group, Inc. (CHAG), closed Monday's trading at $0.025, up 25.00%, on 130,000 volume with 5 trades. The average volume for the last 60 days is 49,272 and the stock's 52-week low/high is $0.005/$0.03.

Petra Petroleum, Inc. (PTL.V)

We are highlighting Petra Petroleum, Inc. (PTL.V), here at the QualityStocks Daily Newsletter.

Headquartered in Vancouver, British Columbia, Petra Petroleum, Inc. is an oil and gas exploration and development company. They engage in the evaluation, acquisition, exploration, and development of oil and gas properties primarily in the Mediterranean, North Africa, and the Middle East regions. The Company plans to grow through the creation of an inventory of high potential exploration interests, and the acquisition of proven assets to achieve early cash flow. Founded in 2008, Petra Petroleum lists on the TSX Venture Exchange.

The Company is focusing on high impact exploration operations in both emerging and proven oil and gas basins of the Mediterranean Rim. Petra believes that the Mediterranean Rim region offers excellent value growth opportunities. The Company has applied for several exploration licenses in Spain, Cyprus and Greece. Other areas of interest include Lebanon, Tunisia, Egypt, Morocco, Oman and Italy.

Concerning Cyprus Offshore, 12 blocks are offered in the Levantine
Basin and adjacent areas. These include the Deep Nile Basin and the Herodotus Basin. Petra has several applications submitted in May 2012 with 100 percent working interest and they are awaiting a Ministry decision.

As pertains to Lebanon Offshore, the license round is expected in late 2012 or early 2013. Petra Petroleum is looking to join a bidding consortium. Concerning Spain Offshore, the Company submitted a number of applications in May 2012 with 100 percent working interest and is awaiting a Ministry decision.

Relating to Greece Onshore, a joint application (Petra 20 percent and Energean Oil & Gas 80 percent) was submitted in July 2012 for a large contract area – the Ioaninna Block. In the North Sea, several oil and gas assets (producing and development) are currently undergoing evaluation for potential acquisition.

In late July 2012, Petra Petroleum announced the appointment of Mr. Andrew Boetius as Chief Financial Officer of the Corporation to replace Mr. John Downes who moved into the role of Manager, Finance and Accounting. Mr. Boetius was previously Director, Finance & Administration since joining the Company in September 2011.

Petra Petroleum, Inc. (PTL.V), closed Monday's session at $0.35, up 16.67%, on 21,000 volume. The stock's 52-week low/high is $0.20/$0.47.

Digerati Technologies, Inc. (DTGI)

AllPennyStocks, OTCPicks, and SmallCapVoice reported earlier on Digerati Technologies, Inc.(DTGI), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Bulletin Board, Digerati Technologies, Inc. is an established and award-winning provider of cloud communication services. The Company meets the international communication needs of businesses that are looking for simple, flexible, and cost effective solutions. Digerati is a three-time recipient of Deloitte and Touche's Fast 500 Award for recognition as one of the 500 fastest growing technology companies in North America. Digerati Technologies has their headquarters in San Antonio, Texas.

Digerati was formerly ATSI Communications, Inc., a global telecommunications carrier founded in 1994. The Company's worldwide network began in 1994 along the United States-Mexico corridor to capitalize on the opportunities created by the deregulation of the telecommunications industry within Latin America. Over the course of the next decade, Digerati expanded their next-generation Voice over Internet (VoIP) network into more than 50 countries. They established more than 200 worldwide partnerships with foreign carriers and emerging operators. In 2010, they expanded beyond their VoIP transport services through introducing their "Only in the Cloud...™" telephony product line.

The Company's cloud-based services include a fully hosted IP/PBX, VoIP transport, SIP trunking, data storage, and customized VoIP solutions for specialized applications. Services are delivered with premier reliability and performance over Digerati's carrier-class global VoIP network.

Digerati's Only in the Cloud...™ communications platform replaces traditional phone systems with a user-friendly system that is completely off-premise in the Internet cloud. This communications platform provides advanced call routing services without the need for end users to handle any technical aspects of managing their telephone system.

The Only in the Cloud...™ telephony solution provides users with a broad array of features. These include customized greetings with sophisticated IVR (Interactive Voice Response) messages, music on hold, voicemail to email, call forwarding, simultaneously ring multiple phones at once, conference calling, call recording, click to call, and several other features. This telephony solution makes advanced technology and Fortune 500 features available to small businesses for a fraction of the cost.

Last Friday, Digerati Technologies announced that they entered into a transaction in anticipation of a definitive agreement for a business combination through the acquisition of 100 percent of the outstanding capital stock of Waste Deep, Inc. The stockholders of Waste Deep will receive newly issued shares of Digerati preferred stock that will be convertible into Digerati Common Stock shares. Waste Deep is an oil field services enterprise with an initial focus in the Bakken Formation.

The business combination will not affect Digerati Technologies' current operations and customers. The Company will continue to provide cloud communication services by way of their operating subsidiaries. Because of the transaction, Digerati will be in a position to provide their cloud-based telephony services to the fast expanding Oil and Gas industry.

Digerati Technologies, Inc. (DTGI), closed Monday's trading session at $0.0032, up 60.00%, on 7,347,140 volume with 96 trades. The average volume for the last 60 days is 96,157 and the stock's 52-week low/high is $0.0001/$0.085.

graphic

The QualityStocks
Company Corner

graphic
graphic

The Guitammer Company Inc. (GTMM)

The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.25, even with yesterday's close, on 10,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 9,189, and its 52-week low/high is $0.082/$0.35.

The Guitammer Company Inc. (GTMM) is a leader in low-frequency sound products and technology. The company’s award-winning line of patented ButtKicker brand audio transducers let users actually feel the excitement, impacts, special effects, and bone-rattling bass brought by its immersive “4D” patent-protected technology. Guitammer’s products are well known for being musically accurate, powerful, and virtually indestructible.

The Guitammer Company was founded in 1990 by Ken McCaw, an accomplished musician, composer, and producer. Joining forces with Marvin Clamme, former sound engineer for Tom Jones and Merle Haggard, Ken and Marvin developed the original ButtKicker transducer prototypes in 1994.

Today, the ButtKicker brand products are used around the world by leading entertainment and theater companies, including AMC, IMAX, and Disney, in movie theaters and attractions. 85 entertainment locations in 11 countries have incorporated ButtKicker products to-date, providing the ultimate experience to over 10,000 seats. The products are also used in home theaters, simulators, and car audio applications.

Guitammer’s technology is compatible to virtually any digital source, including cable, satellite, fiber optic, IPTV, “over-the-air” broadcast, video games, and audio CDs. The ButtKicker brand products add unparalleled realism and excitement to movies, music, and games. Guitammer’s low-frequency, high-impact sound innovation is the next logical step after HDTV, 3DTV, and TiVo, bringing ground-breaking changes in how consumers enjoy their entertainment. Disclaimer

The Guitammer Company Inc. Company Blog

The Guitammer Company Inc. News:

Guitammer Third Quarter Revenue More Than Triples To $555,000

Guitammer CEO Mark Luden to Present at 7th Annual Singular Research 'Best of the Uncovereds' Conference in Los Angeles

Lumiere Pavilions Continues Rapid Expansion of ButtKicker® Footprint, Adding Sixth and Seventh Theater Installations of Guitammer's Patented "4D" Technology

VIASPACE, Inc. (VSPC)

The QualityStocks Daily Newsletter would like to spotlight VIASPACE, Inc. (VSPC). Today, VIASPACE, Inc. closed trading at $0.0115. The stock’s average daily volume over the past 60 days is 1,536,998, and its 52-week low/high is $0.0013/$0.015.

VIASPACE, Inc. reported today that they have successfully engaged top Small-Cap and Micro-Cap online Investment Newsletter collator, QualityStocks, which is also a tireless proponent for emerging public companies, helping such companies to obtain exposure and establish market presence. QualityStocks will assist VSPC in maximizing investor communication efforts, allowing the company to connect directly with a 1M strong and growing user base in real-time through a continuous stream of media and content that allows the investment community to discover emerging companies. QualityStocks will help VIASPACE bring the revolutionary potential of their Giant King™ Grass as a low-carbon, fast up cycle input for clean energy generation and bio-methane production, as well as other green cellulosic biofuels, in addition to biochemical and biomaterial applications.

VIASPACE, Inc. (VSPC) is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.

The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.

VIASPACE provides Giant King™ Grass seedlings and technical expertise to qualified projects. The company also plans to serve as a project developer or co-developer for power plant or pellet mill projects, together with local partners that have land and require electricity, heat, pellets, biogas, or biofuels. VIASPACE and its partners are capable of delivering an integrated Giant King Grass plantation and biomass power plant project in just 24 months.

The excellent energy characteristics of Giant King Grass and its ability to be harvested multiple times each year enable and energy output yield that is much higher than other crops . This superior feedstock offers material productivity benefits at remarkable costs for energy production, biofuels, and biomaterials. Giant King Grass is currently being grown in the United States, Virgin Islands, China, and other areas. Disclaimer

VIASPACE, Inc. Company Blog

VIASPACE, Inc. News:

VIASPACE, Inc. Announces Engagement of QualityStocks Investor Relations Services

Renewable Giant King Grass is Growing in St. Croix; VIASPACE Now on Facebook and Twitter

VIASPACE CEO Presents at Asian Development Bank Renewable Energy Conference and Meets Customers in Myanmar

Cardium Therapeutics, Inc. (CXM)

The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.205, up 5.72%, on 11,300 volume with 28 trades. The stock’s average daily volume over the past 60 days is 16,604, and its 52-week low/high is $0.1771/$0.595.

Cardium Therapeutics, Inc. reported on winning a key patent in Europe today, in conjunction with the successful resolution of a long-standing competition over the rights to key methods for the application of cardiovascular gene therapy for treating coronary heart disease (as employed in Cardium's Generx® gene therapy candidate, currently in late-stage clinical studies). The decision by the European Patent Office adds substantial territory to CXM's IP portfolio. The resolution of the competition between CXM and its licensor the University of California with Boston Scientific Corporation (BSX) and its licensor Arch Development clears away the debris and roundly affirms CXM's patent position, especially in light of consistent rulings by the U.S. courts of appeal. Dr. Tyler M. Dylan-Hyde, CBO and General Counsel for CXM, called Generx a potential breakthrough approach to the treatment of coronary heart disease and we should get a better sense of this post the current Phase 3 registration trial in Moscow (designed in large part to generate safety and effectiveness data for the Russian Federation and other jurisdictions).

Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.

The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.

Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.

Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer

Cardium Therapeutics, Inc. Company Blog

Cardium Therapeutics, Inc. News:

"Cardium Announces Patent Award For Rights To Gene Therapy for Coronary Heart Disease, Resolves Long-standing IP Competition"

Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments

Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference

DoMark Internatioxnal, Inc. (DOMK)

The QualityStocks Daily Newsletter would like to spotlight DoMark International, Inc. (DOMK). Today, DoMark International, Inc. closed trading at $0.39, on 20,900 volume with 2 trades. The stock’s average daily volume over the past 60 days is 19,951, and its 52-week low/high is $0.32/$4.88.

DoMark International, Inc. subsidiary, SolaWerks Inc., reported launch of a brand new website today (IRcharger.com), following fast on the heels of their recently announced, patent pending INFRASOL™ technology, a key infrared spectrum gathering technology that allows their Apple iPhone 4/4S and iPhone 5 solar charger/covers, the SolaCase™, to also harvest infrared light (which accounts for nearly half the total light energy output of the sun). The completely overhauled SolaWerks website, IRcharger.com, is intended to support the launch of the latest INFRASOL enabled products, not only helping to organically promote this amazing new technology that will power mobile devices off a previously unutilized spectrum of energy through things like the new Affiliate Program, but also helping consumers select the proper SolaWerks products to go with their device(s).

DoMark International, Inc. (DOMK) is focused on researching, evaluating, and acquiring profitable private firms in the business segments of sports, technology, medical, energy, and business services. By providing the financial and human capital necessary to deal with overwhelming administrative, planning, governance, compliance, and regulatory challenges, its newly acquired partners can focus their energy and flourish.

Through its wholly owned subsidiary, SolaWerks, Inc., DoMark is committed to revolutionizing the efficiency and capabilities of a new generation of mobile devices. The subsidiary's current focus is on developing and distributing the SolaPad, a combined cover and charging system for Apple's iPad, and the SolaCase, a combined cover and charging system for all versions of Apple's iPhone.

Musclefoot, Inc., another wholly owned subsidiary of DoMark, is engaged in the distribution, marketing, and sale of Barefoot Science, the revolutionary patented foot care system designed to relieve foot and back pain as well as improve athletic performance. With a strong commitment to customer service and security, DoMark plans to expand its marketing relationships across a far broader product set.

The management team has positioned the company to capitalize on emerging opportunities by working with the world's most forward-thinking companies to develop and market game-changing products with the promise of long-term financial growth. Leveraging the expertise of its team, the company continues to evaluate acquisition candidates and products targeting underserved markets to increase its growth potential. Disclaimer

DoMark International, Inc. Blog

DoMark International, Inc. News:

DoMark International Subsidiary and Leader in Infrared/Solar Apple Accessories, SolaWerks™, Launches New Website

SolaWerksTM Extending Lead in Mobile Energy by Adding Infrared to Its Solar Powered Apple Accessory Products

DoMark Subsidiary SolaWerks Next Generation Technology Slated for Release

The Guitammer Company Inc. (GTMM) is “One to Watch”

The Guitammer Company is a leader in low-frequency sound products and technology. The company’s award-winning line of patented ButtKicker brand audio transducers let users actually feel the excitement, impacts, special effects, and bone-rattling bass brought by its immersive “4D” patent-protected technology. Guitammer’s products are well known for being musically accurate, powerful, and virtually indestructible.

The Guitammer Company was founded in 1990 by Ken McCaw, an accomplished musician, composer, and producer. Joining forces with Marvin Clamme, former sound engineer for Tom Jones and Merle Haggard, Ken and Marvin developed the original ButtKicker transducer prototypes in 1994.

Today, the ButtKicker brand products are used around the world by leading entertainment and theater companies, including AMC, IMAX, and Disney, in movie theaters and attractions. 85 entertainment locations in 11 countries have incorporated ButtKicker products to-date, providing the ultimate experience to over 10,000 seats. The products are also used in home theaters, simulators, and car audio applications.

Guitammer’s technology is compatible to virtually any digital source, including cable, satellite, fiber optic, IPTV, “over-the-air” broadcast, video games, and audio CDs. The ButtKicker brand products add unparalleled realism and excitement to movies, music, and games. Guitammer’s low-frequency, high-impact sound innovation is the next logical step after HDTV, 3DTV, and TiVo, bringing ground-breaking changes in how consumers enjoy their entertainment.

VIASPACE, Inc. (VSPC) Engages QualityStocks Investor Relations Services

VIASPACE just announced that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs, and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts.

VIASPACE is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.

The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.

Dr. Carl Kukkonen, CEO of VIASPACE, commented, “VSPC has a unique and solid business foundation, and appreciates the opportunity to sponsor the QualityStocks Newsletter, Video and Blogs. QualityStocks is providing a much needed service in the micro-cap and small-cap markets.”

For more information, visit www.viaspace.com

Cardium Therapeutics, Inc. (CXM) Wins IP Protection for Cardiovascular Gene Therapy

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, today announced it was on the winning side of a patent decision made in Europe. This decision resolved a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy to the treatment of coronary heart disease. Cardium’s Generx® gene therapy candidate, which employs these key methods, is currently in late-stage clinical studies.

Cardium’s patent portfolio now includes allowed and issued patents covering its gene therapy approach both in Europe and in the United States, with competing patent applications licensed and pursued by Boston Scientific having been successfully overcome in both Europe and the U.S.

The competing patent applications licensed by Boston Scientific Corporation had been the subject of opposition proceedings in Europe and interference proceedings in the United States, both of which were ultimately resolved in Cardium’s favor. After further examining Cardium’s case, the European Patent Office approved Cardium’s patent application for grant in Europe. Three corresponding U.S. Patents that had been challenged by Boston Scientific Corporation have been affirmed in the favor of Cardium.

Cardium has additional patents and patent applications involving its methods of cardiovascular gene therapy in the U.S., Europe, Russia, and in other parts of the world, and the company recently filed new patent applications involving certain improved techniques for the treatment of heart disease that are currently the subject of a Phase 3 registration trial based in Moscow, which is designed to generate additional safety and effectiveness data for the Russian Federation and other jurisdictions. Generx® (alferminogene tadenovec) is intended to stimulate the growth of collateral blood vessels to effectively bypass coronary artery atherosclerotic blockages without the need for surgical procedures or angioplasty and stents. Its safety and effectiveness have been the subject of clinical studies involving more than 650 patients in the U.S., Europe, and elsewhere. Generx has been assigned the trade name Cardionovo™ for planned commercialization in the Russian Federation. Cardium believes that its Generx clinical database represents the largest and most complete gene therapy dossier and is directed to a major medical indication that is a leading cause of death throughout the developed world.

“The resolution of these important reviews of our gene therapy patents, and the consistent decisions in our favor including rulings by the U.S. courts of appeal, underscore the value of our patent portfolio, which we believe reflects a breakthrough approach to the treatment of coronary heart disease,” stated Dr. Tyler M. Dylan-Hyde, Chief Business Officer and General Counsel of Cardium Therapeutics.

Recently-published findings demonstrate that Cardium’s innovative technique employing transient cardiac ischemia can be used to dramatically enhance gene delivery and transfection efficiency after one-time intracoronary administration of adenovector in mammalian hearts. Two consecutive but brief periods of coronary artery occlusion combined with co-administration of nitroglycerin increased both adenovector presence (measured by PCR) and transgene expression (assessed by luciferase activity) by over two orders of magnitude (>100 fold) in the heart, as compared to prior intracoronary artery delivery methods.

The research results published in Human Gene Therapy Methods extend those findings and demonstrate that Cardium’s new technique for adenovector gene delivery in the heart can be used to dramatically boost adenovector delivery. By enhancing uptake even in patients with less severe forms of disease and ischemia, it would be expected to reduce response variability and allow for the potential treatment of patients with a broader range of associated coronary artery disease. The new treatment protocols for Cardium’s recently-initiated ASPIRE clinical study have been developed to use this improved knowledge about induced transient ischemia techniques to enhance the non-surgical, catheter-based delivery of Generx to the heart.

Cardium has also been actively advancing its Generx product candidate’s engineering and process technology in preparation for commercialization. The company successfully transferred a refined, improved, and fully-validated manufacturing process to SAFC®, the custom manufacturing and services business unit of Sigma-Aldrich Corporation (NASDAQ: SIAL), a top global specialty chemicals and biologics supplier, located in Carlsbad, California. As a result of the rigorous technical transfer process, important process improvements were achieved enabling much higher manufacturing process yields. Generx’s long-term product stability has been established at a minimum of six years making it possible to manufacture product in large, cost effective batch sizes. The dose preparation process for Generx has been simplified through the integration of a fully-validated, closed-system drug transfer process incorporating the use of PhaSeal® System passive safety technology to streamline and simplify the cath-lab preparation and eliminating the need to prepare Generx in a sterile, biological safety hood. The company has also developed a new and unique, fully-validated bio-activity release assay to measure and evaluate the pro-angiogenic potency of each newly manufactured batch of Generx.

The European Commission’s recent approval of uniQure’s Glybera® (alipogene tiparvovec) – the first gene therapy approval by a major health regulatory authority – is considered to represent a significant milestone and validation for the gene therapy industry.

For more information, visit www.cardiumthx.com

DoMark International, Inc. (DOMK) Subsidiary Launches New Website to Promote Infrared/Solar Apple Accessories

SolaWerks, a subsidiary of DoMark International primarily focused on infrared/solar charging systems for Apple devices, announced the launch of a brand new website, IRcharger.com. Today’s news comes shortly after last week’s announcement introducing SolaWerks’ innovative, patent-pending INFRASOL technology, which utilizes infrared energy to power the latest Apple iPads and iPhones.

IRcharger.com will help the company increase awareness of the most cutting-edge, most environmentally friendly, and most cost effective mobile device charging system available. The new website was developed to offer the user easier navigation, educational tools, and a more enjoyable experience while shopping for INFRASOL-enabled SolaWerks cover/charger systems.

IRcharger.com was launched to help support the introduction of the latest INFRASOL enabled products – starting with the latest SolaCase for the iPhone 4/4S and the new iPhone 5 platforms. Unlike traditional solar power, INFRASOL technology harnesses the energy of infrared light, which makes up close to half the light emitted by the sun. In addition to capturing energy from the sun, INFRASOL powered devices can also be charged by incandescent light and even the Earth itself – the INFRASOL revolution promises to enable a wireless world once and for all.

Manufacturing of the SolaCase for the latest iPhone platforms is already well underway, and the company anticipates heavy volume at the new IRcharger.com website. The company is extremely excited about its new Affiliate Program as well, which offers users a chance to help spread the SolaWerks message and earn rewards at the same time. SolaWerks will announce more details regarding the program very soon.

“Shopping for Apple accessories can be an intimidating task with so many different accessory products on the market, so we developed these tools to eliminate any uncertainty and answer some of the tougher, technical questions,” stated Andy Ritchie, President of SolaWerks’ parent company, DoMark International. “We believe our fresh, clean cut new website will be both an enjoyable site to visit and easier way to purchase the revolutionary SolaWerks product line.”

According to ABI Research, the Apple accessory market raked in $5-$6 billion of the estimated $34 billion 2011 global mobile device accessory market. “SolaWerks is committed to continuous improvement in the Apple accessory market, and our new website is another stepping stone along that path,” said Mr. Ritchie.

For more information on SolaWerks or to inquire about its products, visit www.IRcharger.com

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

PennyStockCrowd
(WCYN)

2.

The Stock Psycho
(GWYT)

3.

Investor Ideas
(MWWC)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251